Cognitive evolution in natalizumab-treated multiple sclerosis patients

Authors: Francois H Jacques, Brian T Harel, Adrian J Schembri, Chantal Paquette, Brigitte Bilodeau, Pawel Kalinowski, Reshmi Roy

Journal: Multiple Sclerosis Journal - Experimental Translational and Clinical

Year Published: 2017

Background: Cognitive dysfunction affects up to 65% of multiple sclerosis (MS) patients and progresses over time. Natalizumab has been shown to be superior to placebo in preserving cognition for the first two years of therapy. Objectives: […]

Back to Publications